Logo

Verve Entered into an Exclusive Research Collaboration with Eli Lilly to Advance In Vivo Gene Editing Program Targeting Lp(a) for Atherosclerotic Cardiovascular Disease

Share this
Eli Lilly

Verve Entered into an Exclusive Research Collaboration with Eli Lilly to Advance In Vivo Gene Editing Program Targeting Lp(a) for Atherosclerotic Cardiovascular Disease

Shots:

  • Verve will receive $60M in up front & equity investment & is also eligible to receive ~$465M in research, development, and commercial milestones along with royalties on global net sales. The companies focused to advance preclinical stage in vivo gene editing program targeting lipoprotein(a) (Lp(a))
  • Verve gets the opt-in rights to co-fund and share margins globally on the Lp(a) program & will advance the R&D of the Lp(a) program upon the completion of P-I clinical trials. Lilly will lead the subsequent development, manufacturing, and commercialization of the Lp(a) program
  • The companies continue to develop a much-needed treatment option for patients with elevated levels of Lp(a)

Ref: Globenewswire | Image: Eli Lilly

Related News:- Vertex Entered into an Exclusive Four-Year Research Collaboration with Verve Therapeutics to Develop an In Vivo Gene Editing Program for Liver Disease

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Senior Editor

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions